Nurix Therapeutics (NRIX) highlighted the Company’s achievements in 2025 and outlined key objectives and anticipated milestones for 2026. Key highlights include: Execute a program for BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic lymphocytic leukemia; Expand bexobrutideg into autoimmune and inflammatory indications, targeting IND submission in 2026 with a new tablet formulation; Advance a growing portfolio of partnered inflammation and immunology programs, including potent and selective degraders of IRAK4 and STAT6; Leverage DEL-AI platform to drive discovery against high-value targets across internal and partnered programs
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley
- Nurix Therapeutics Advances Study for NX-5948 in CLL and SLL Patients
- HOOD, IBTA, IRDM: Cathie Wood Buys the Dip in Robinhood, Sells Ibotta and Iridium Stocks
- Cathie Wood Capitalizes the Surge in Iridium and Biotech Stocks
- Nurix Therapeutics price target raised to $30 from $24 at Mizuho